Organogenesis Holdings

ORGO · NASDAQ

$1.02+$0.00 (+0.00%)TodayMarket closed ·
Prev close $1.02

Latest news

  • Press releaseGlobe Newswire

    Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • NewsAvi Kapoor

    Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

  • NewsAvi Kapoor

    Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket

  • News

    12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

  • NewsAvi Kapoor

    Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

  • NewsAvi Kapoor

    Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

  • Press releasePRNewswire

    One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics

  • Press releaseGlobe Newswire

    Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

  • Press releaseGlobe Newswire

    Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild Itself

  • Press releaseGlobe Newswire

    The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

  • Press releasePRNewswire

    The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

  • Press releaseGlobe Newswire

    Organogenesis Holdings, Inc. Investigated by the Portnoy Law Firm

  • NewsVandana Singh

    What's Going On With Organogenesis Stock On Wednesday?

  • NewsVandana Singh

    Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win

  • Press releaseGlobe Newswire

    Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

  • News

    A Preview Of Organogenesis Hldgs's Earnings

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releasePRNewswire

    Avista Healthcare Partners Announces Promotions

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • News

    Market-Moving News for December 16th

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

  • News

    Earnings Scheduled For November 6, 2025

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releaseBusiness Wire

    Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

  • Press releaseGlobe Newswire

    Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

  • Press releaseGlobe Newswire

    Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

  • Press releaseGlobe Newswire

    Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

  • Press releaseGlobe Newswire

    Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.